Printer Friendly

DRAXIS Reports Presentation of Interim Phase II Results of Fibrimage at Society of Nuclear Medicine Meeting.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--June 16, 1999--

DRAXIS Health Inc. (NASDAQ:DRAXF) (TSE:DAX.) announced today that the investigators involved in the Phase II study of Fibrimage(R), a novel Technetium-99m radiopharmaceutical for the imaging of active thrombus in Deep Vein Thrombosis (DVT), presented their interim results at the Society of Nuclear Medicine Meeting held in Los Angeles last week.

Based on the interim results, the investigators concluded that Fibrimage(R) is a new and very promising radiopharmaceutical for the detection of DVT.

Fibrimage(R) is the lead product among several radiopharmaceuticals under development by DRAXIMAGE Inc., the DRAXIS radiopharmaceutical subsidiary.

Patient qualification for the Phase II study was based on a presumptive diagnosis of DVT supported by an ultrasound and a positive d-dimer test, whether the patient was on heparin or not. All qualifying patients were then injected with Fibrimage(R) and subjected to imaging 30 minutes, 2 hours and 4-6 hours following injection.

Interpretations of the images were carried out by three separate blinded experienced observers who made their interpretation without reference to any other clinical information.

For the first 18 patients in the Phase II study, the imaging procedure utilizing Fibrimage(R) had a positive correlation with the initial diagnosis of 72 percent after 30 minutes and 84 percent overall.

The investigation was reported on by Dr. R. Taillefer, MD, FRCP, ABNM, of the Centre Universitaire de Montreal Campus Hotel Dieu, Montreal, Canada reporting on behalf of himself and his co-investigators Drs. R. Lambert, L. Boucher, P. Wells, A. Driedger, and M. Kovacs.

The Company expects that the Phase II study target enrollment will be completed this quarter and to commence Phase III studies in the third quarter of 1999.

DRAXIS Health Inc. is a diversified and fully integrated pharmaceutical company operating in three niche markets: Companion Animal Health (through its global alliance with Pfizer Inc.) Radiopharmaceuticals (DRAXIMAGE) and Canadian sales and marketing (DRAXIS Pharmaceutica). DRAXIS supports its own as well as third party manufacturing requirements through its subsidiary, DRAXIS Pharma, located in Kirkland, Quebec.

Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties, which may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, changing market conditions, clinical trial results, the establishment of new corporate alliances, the impact of competitive products and pricing, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time-to-time in the Company's filings with the U.S. Securities and Exchange Commission and Canadian securities authorities.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Jun 17, 1999
Words:427
Previous Article:Onsale and Intuit Launch Live Auction Feed to Quicken.com; Wholesale Computer Equipment and Other Products Available To Small Businesses Online.
Next Article:Flushing Financial Corporation Announces Sixth Stock Repurchase Program.
Topics:


Related Articles
DRAXIS Begins Phase III Clinical Trials for Fibrimage.
DRAXIS Files for Canadian Regulatory Approval for Brachytherapy Seeds.
DRAXIS Files Investigational New Drug Application for AMISCAN.
DRAXIS Receives Key U.S. Patent for BrachySeed(TM).
DRAXIS Commences Phase I Clinical Study For AMISCAN.
DRAXIS Receives Canadian Nuclear Safety Commission Approval for BrachySeed Prostate Cancer Treatment Canadian Shipments to Commence This Quarter.
DRAXIS Commences Phase II Clinical Study For AMISCAN.
DRAXIS Appoints New President Of DRAXIMAGE Subsidiary.
DRAXIS Commences Production in New Lyophilization Facility.
DRAXIS Receives FDA Approval For In-House Manufacture Of Lyophilized Products.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters